Understanding your results
When the Agendia Breast Cancer Test Suite is ordered, you are provided a detailed result report for every assay (MammaPrint & BluePrint). In addition to the individual reports, a summary page is included to consolidate the 2 test results, and to provide additional clinical information for the treating physician. The purpose of the summary page is to help the clinician discuss and explain an individual patient’s results.
Please see the descriptions below to learn more about the results you may receive. Samples of the different reports are located at the end of this page.
Understanding Your Breast Cancer Patient’s Risk of Recurrence Result
MammaPrint analyzes the 70 critical genes identified in breast cancer metastasis to determine a woman’s biological risk of recurrence. MammaPrint provides a definitive result, Low Risk or High Risk, which is significantly correlated with differences in probability of metastasis free survival.
Many surgeons and oncologists rely on MammaPrint with other clinical criteria to assist in their therapeutic decision making. When combined with traditional risk factors, if a breast cancer patient is Low Risk by MammaPrint, endocrine therapy (e.g. Tamoxifen) alone may be sufficient to further reduce her recurrence risk. Conversely, if a breast cancer patient is High Risk by MammaPrint and has additional risk factors, she may benefit from more aggressive treatment including chemotherapy.
MammaPrint Low Risk Result:
A “Low Risk” MammaPrint result means that a patient has on average a 10% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy.9
MammaPrint High Risk Result:
A “High Risk” MammaPrint result means that a patient has a 29% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy.9